澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Imagion Biosystems

0.021

+0.0015.00%

成交量：8.01萬

成交額：1,613.00

市值：1,030.24萬

市盈率：-1.35

高：0.021

開：0.020

低：0.020

收：0.020

52周最高：0.055

52周最低：0.011

股本：4.91億

流通股本：1.72億

量比：0.03

換手率：0.05%

股息：- -

股息率：- -

每股收益(TTM):-0.016

每股收益(LYR):-0.016

淨資產收益率：-2804.87%

總資產收益率：-90.55%

市淨率：-4.77

市盈率(LYR):-1.35

資料載入中...

總覽公司新聞資訊公告

醫學影像公司Imagion Biosystems向FDA提交Magsense® Her2靶向顯影劑二期試驗新藥臨床試驗申請

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IBX.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IBX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IBX.AU\",,,,,undefined,":{"symbol":"IBX.AU","market":"AU","secType":"STK","nameCN":"Imagion Biosystems","latestPrice":0.021,"timestamp":1774588320000,"preClose":0.02,"halted":0,"volume":80121,"delay":0,"changeRate":0.050000000000000044,"nameEN":"Imagion Biosystems","floatShares":172453894,"shares":490590239,"eps":-0.01553,"marketStatus":"休市中","change":0.001,"latestTime":"03-27 16:12:00 AEDT","open":0.02,"high":0.021,"low":0.02,"amount":1613,"amplitude":0.05,"askPrice":0.021,"askSize":189531,"bidPrice":0.02,"bidSize":49321,"shortable":3,"etf":0,"ttmEps":-0.01553,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.02,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0.027747,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IBX.AU","preClose":0.019,"auctionPrice":0.02,"auctionVolume":50903,"auction":3,"marketStatus":"盘后竞价","timestamp":1774501445882}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IBX.AU\",,,,,undefined,":{"symbol":"IBX.AU","floatShares":172453894,"roa":"-90.55%","roe":"-2804.87%","lyrEps":-0.01553,"volumeRatio":0.027747,"shares":490590239,"dividePrice":0,"high":0.021,"amplitude":0.05,"preClose":0.02,"low":0.02,"week52Low":0.011,"pbRate":"-4.77","psRate":"141.07","week52High":0.055,"institutionHeld":0,"latestPrice":0.021,"committee":-0.587016,"eps":-0.01553,"divideRate":0,"volume":80121,"delay":0,"ttmEps":-0.01553,"open":0.02,"prevYearClose":0.025,"prevWeekClose":0.019,"prevMonthClose":0.023,"prevQuarterClose":0.025,"fiveDayClose":0.019,"twentyDayClose":0.023,"sixtyDayClose":0.025,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-11-16","symbol":"IBX.AU","defaultRemindTime":1700089200000,"type":"split","dateTimestamp":1700053200000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1161971983","title":"醫學影像公司Imagion Biosystems向FDA提交Magsense® Her2靶向顯影劑二期試驗新藥臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1161971983","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161971983?lang=zh_tw&edition=fundamental","pubTime":"2026-02-04 00:30","pubTimestamp":1770136219,"startTime":"0","endTime":"0","summary":"医学影像技术企业Imagion Biosystems（ASX: IBX）已正式向美国食品药品监督管理局（FDA）提交新药临床试验申请（IND），计划开展其旗舰产品Magsense® Her2靶向显影剂的二期临床试验。该显影剂采用创新纳米技术，旨在通过高精度磁共振成像实现对HER2阳性肿瘤的早期识别与定位，为乳腺癌等癌症的精准诊疗提供新方案。此次IND获批后将启动多中心临床研究，进一步验证该显影剂的安全性与成像效能，有望填补现有HER2检测技术的可视化诊断空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","IBX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}